Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease.

Edmond TengPaul T ManserSandra Sanabria BohorquezKristin R WildsmithKaren PickthornSuzanne L BakerMichael WardGeoffrey A KerchnerRobby M Weimer

Published in: Alzheimer's research & therapy (2021)

Our results suggest that [18F]GTP1 tau PET represents a prognostic biomarker in AD and are consistent with data from other tau PET tracers. Tau PET imaging may have utility for identifying AD patients at risk for more rapid cognitive decline and for stratification and/or enrichment of participant selection in AD clinical trials. Trial registration ClinicalTrials.gov NCT02640092 . Registered on December 28, 2015.

Keyphrases

cognitive decline
pet imaging
mild cognitive impairment
cerebrospinal fluid
clinical trial
positron emission tomography
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
phase ii
prognostic factors
phase iii
study protocol
artificial intelligence
quantum dots